PMID- 28382107
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 10
IP  - 2
DP  - 2017 Feb
TI  - Tetrabenazine in treatment of hyperkinetic movement disorders: an observational 
      study.
PG  - 81-90
LID - 10.1177/1756285616677004 [doi]
AB  - BACKGROUND: Tetrabenazine (TBZ) is commonly used in hyperkinetic movement 
      disorders. In this retrospective study, we aimed to assess the TBZ effectiveness 
      and adverse events (AEs) in Huntington disease (HD), vascular chorea, tics, 
      dystonia, tardive oromandibular (OM) dyskinesia and other tardive syndromes (TS). 
      METHODS: Qualitative analysis of clinical response was used to estimate TBZ 
      effectiveness. TBZ-associated AE frequency and subsequent discontinuation rate 
      were used to estimate tolerability; the tolerability profile was measured through 
      the TBZ minimal dose and exposure time required to elicit AEs. RESULTS: Of 108 
      included patients, 87% had a clinically meaningful improvement sustained over a 
      period of 40 months. TBZ-responder rate ranged from 100% in HD to 62.5% and 77.1% 
      in tic disorders and OM dyskinesia, respectively (p < 0.001). TBZ-associated AE 
      frequency ranged from 40.9% in other TS and 41.7% in vascular chorea and HD, to 
      60% in OM dyskinesia (p < 0.001). The most common AEs were Parkinsonism (51.8%) 
      and psychiatric disorders (25%). The 'other AEs' category (mainly somnolence) 
      presented the shortest minimal exposure time (3 months). AE-eliciting dose 
      differed from 18.8 mg and 25 mg in tics and tardive disorders, to 75 mg in HD (p 
      = 0.003). Patients with AEs were tendentiously older at TBZ initiation (p = 
      0.022). CONCLUSIONS: TBZ proved an effective and relatively well tolerated 
      treatment in hyperkinetic disorders, with excellent results in HD. AEs were more 
      common in OM dyskinesia, which may be related to higher age at TBZ initiation. 
      TBZ-associated somnolence and Parkinsonism were more frequent during the 
      titration and maintenance periods, respectively.
FAU - Miguel, Rita
AU  - Miguel R
AD  - Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa 
      Ocidental, Rua da Junqueira, 126, 1349-019, Lisbon, Portugal.
FAU - Mendonca, Marcelo D
AU  - Mendonca MD
AD  - Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa 
      Ocidental, Lisbon, Portugal CEDOC, Nova Medical School/ Faculdade de Ciencias 
      Medicas, Universidade Nova de Lisboa, Lisbon, Portugal.
FAU - Barbosa, Raquel
AU  - Barbosa R
AD  - Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa 
      Ocidental, Lisbon, Portugal.
FAU - Ladeira, Filipa
AU  - Ladeira F
AD  - Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa 
      Ocidental, Lisbon, Portugal.
FAU - Lampreia, Tania
AU  - Lampreia T
AD  - Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa 
      Ocidental, Lisbon, Portugal.
FAU - Vale, Jose
AU  - Vale J
AD  - Department of Neurology, Hospital Beatriz Angelo, Avenida Carlos Teixeira, 
      Loures, Portugal.
FAU - Bugalho, Paulo
AU  - Bugalho P
AD  - Neurology Department, Hospital Egas Moniz - Centro Hospitalar de Lisboa 
      Ocidental, Lisbon, Portugal CEDOC, Nova Medical School/ Faculdade de Ciencias 
      Medicas, Universidade Nova de Lisboa, Lisbon, Portugal.
LA  - eng
PT  - Journal Article
DEP - 20161121
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC5367646
OTO - NOTNLM
OT  - Huntington disease
OT  - dystonia
OT  - oromandibular dyskinesia
OT  - tardive syndrome
OT  - tetrabenazine
OT  - tics
COIS- Conflict of interest statement: The author(s) declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2017/04/07 06:00
MHDA- 2017/04/07 06:01
PMCR- 2017/02/01
CRDT- 2017/04/07 06:00
PHST- 2017/04/07 06:00 [entrez]
PHST- 2017/04/07 06:00 [pubmed]
PHST- 2017/04/07 06:01 [medline]
PHST- 2017/02/01 00:00 [pmc-release]
AID - 10.1177_1756285616677004 [pii]
AID - 10.1177/1756285616677004 [doi]
PST - ppublish
SO  - Ther Adv Neurol Disord. 2017 Feb;10(2):81-90. doi: 10.1177/1756285616677004. Epub 
      2016 Nov 21.